Anas Younes, MD, from Memorial Sloan Kettering Cancer Center, NY, USA shares the latest data on immune checkpoint inhibitors presented during the summer congresses; ASCO, ICML and EHA. Included in his wrap up is the CHECKMATE 205 trial with nivolumab and the potential for targeting PDL-1 on which there was a Phase 1 trial presented at ICML. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.